Fritextsökning
Innehållstyper
-
He is zooming in on topical preparations
According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting ap...
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
to the outcome of the pilot to hopefully then understand if “in house” analyses actually will add value.
-
Failed to read the fine print – lost his life’s work
A celebrated CEO and co-founder of a pioneering lab company one moment – the next, fired, kicked out and written out of the company’s history. This is the story...
-
Neanderthal genes and Nobel Prize in a popular lecture at Bioscience
An inherited gene variant from our ”evolutionary cousins” – the extinct Neanderthals – may affect how our bodies break down certain drugs. “It’s only a matter o...
-
The fast route to a safe insulin pen
Diabetes is on the rise worldwide with around ten million people developing the disease every year. Demand for insulin pens allowing patients to self-medicate i...
-
Active Biotech avbryter tasquinimod
Avslutar flaggskeppsprojektet tasquinimod – nu väntar personalminskningar.
-
Tougher competition as the Novo Nordisk Foundation broadens its programme
Søren Nedergaard has worked with innovation at the Danish Government Offices and the University of Copenhagen. Today, he is COO of the Novo Nordisk Foundation, ...
-
Active Biotech ändrar fokus
Slutar med fas III-studier och satsar på tidig utveckling.
-
Ökad förlust för Active Biotech
Efter misslyckandet med flaggskeppsprojektet tasquinimod, som lades ner under våren, fortsätter förlusterna för bioteknikbolaget.
-
Active Biotech håller kursen
Bolaget förväntar sig kunna leverera fas III-data som planerat.
-
Anna Törner: Kalashnikovs in a new guise
Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American ph...
-
Fortsatt förlust för Active Biotech
Efter det misslyckade tasquinimod-projektet flyttas fokus till laquinimod och ISI, säger finanschef Hans Kolam.
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...
-
Active Biotech ett hett byte
Blir uppköpta med 15 procents sannolikhet, enligt investmentbanken Goldman Sachs.
-
The first drugs to slow down Alzheimer’s – but what does it mean for patients?
New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...
-
Negativt för Active Biotech-konkurrenten
Novartis MS-preparat Gilenya når inte målet i fas III.
-
Business Sweden’s new team is rolling out the blue-yellow carpet
According to Business Sweden’s life science team, the combination of substantial medical know-how and an ever-flourishing tech sector is a success factor for Sw...
-
Kassaklirr för Active Biotech
Forskningsbolaget kammar hem delmålsbetalning på 104 miljoner kronor.
-
47 får gå från Active Biotech
Varslar och flyttar allt fokus till laquinimod.
-
Cantargia rekryterar från Active Biotech
Lundabaserade biotechbolaget tar in Göran Forsberg som vd och stärker samtidigt kassan med 20 miljoner.
-
Ingen granskning av Active Biotech
Ekobrottsmyndigheten lägger ner förundersökning mot Active Biotech
-
Active faller igen
Aktien rasar efter ett uttalande från bolagets MS-partner Teva.
-
Active Biotech anmäls för ekobrott
Anklagas för att vilseleda aktieägarna om sannolikheten för ett EU-godkännande av MS-preparatet laquinimod.
-
How critical are the “Spermageddon” reports? – Researchers call for action
A much talked about meta-study indicates that sperm concentration in men’s seminal fluid has halved in 40 years. Experts in andrology that Life Science Sweden s...
BREAKING